{"id":8282,"date":"2022-04-20T11:48:02","date_gmt":"2022-04-20T08:48:02","guid":{"rendered":"https:\/\/www.bonalive.com\/en\/?p=8282"},"modified":"2023-05-04T08:32:46","modified_gmt":"2023-05-04T05:32:46","slug":"bonalive-biomaterials-appoints-heidi-rantala-as-new-ceo","status":"publish","type":"post","link":"https:\/\/www.bonalive.com\/en-us\/news\/bonalive-biomaterials-appoints-heidi-rantala-as-new-ceo\/","title":{"rendered":"Bonalive Biomaterials appoints Heidi Rantala as new CEO"},"content":{"rendered":"

After being interim CEO since December 2021, Bonalive\u2019s Board of Directors decided unanimously to place their trust in Mrs. Heidi Rantala <\/strong>as the permanent CEO starting May 1, 2022. Mrs. Rantala has been with the company over 12 years in various roles, including Operations Director and member of the Management Team.<\/p>\n

\u201cFrom day one, Mrs. Rantala has shown a high ambition to build and provide structure to the company with her culture of discipline\u201d, says Executive Chairman and Founder of Bonalive, Dr. Fredrik Ollila.<\/strong><\/p>\n

\u201cI\u2019m very proud to be part of our highly skilled team, enabling a world where infections are treated without antibiotics.\u201d<\/p><\/blockquote>\n

\u201cI\u2019ve had the privilege to witness our transformation towards a growing business. I\u2019m honored to be appointed CEO of Bonalive and look forward to continuing the journey with my colleagues and our partners around the world\u201d, Mrs. Rantala comments.<\/p>\n

\u201cMrs. Rantala presents a character of being self-motivated and driven with an eagerness to learn. These qualities will help us enter the next phase of growth and expansion\u201d, says Dr. Ollila.<\/p>\n

In addition, Bonalive is looking to strengthen its commercial division. \u201cI look forward to welcoming a new Commercial Director to reinforce our development and implementation commercial strategies to accelerate growth\u201d, says Mrs. Rantala.<\/p>\n

\u201cAntimicrobial resistance (AMR) is one of greatest challenges facing healthcare today. I\u2019m very proud to be part of our highly skilled team, enabling a world where infections are treated without antibiotics\u201d,\u00a0 Mrs. Rantala concludes.<\/p>\n

 <\/p>\n

For media, please contact:<\/p>\n

Mrs. Ulla Lumiainen
\nPhone: +358 40 592\u00a09910
\nEmail: ulla.lumiainen[at]bonalive.com<\/p>\n

\"\"
\nBonalive Biomaterials Ltd is a leader in the development of novel antibiotic-free products for bone regeneration in orthopedic and ENT surgery. The company manufactures and sells implantable biomaterials based on S53P4 bioactive glass for bone regeneration. Areas of use include bone infection, diabetic foot osteomyelitis, benign bone tumors, mastoid surgery, and spine surgery. The clinical use of Bonalive\u00ae is supported by a 20-year history of research and more than 200 scientific papers.<\/em><\/p>\n

 <\/p>\n